Novel drugs are rapidly moving forward the treatment-paradigm of non-Hodgkin-lymphomas
(NHLs). Notwithstanding, especially in aggressive subtypes, chemotherapy remains the …

Metronomic chemotherapy (mCHEMO), based on frequent, regular administration of low, but
pharmacologically active drug doses, optimizes antitumor efficacy by targeting multiple …

Abstract Purpose of Review Older patients with diffuse large B-cell lymphoma (DLBCL) may
face challenges in treatment due to comorbidities and tolerance of chemotherapy. Recent …

Introduction Several maintenance therapies are available for treatment of patients with
relapsed/refractory (R/R) diffuse large B cell lymphoma (DLBCL). The objective of this …

Introduction Chimeric antigen receptor T (CAR-T) therapy has revolutionized the treatment of
relapsed/refractory large B-cell lymphoma (LBCL). However, patients who are excluded or …

Background Non-germinal center B-cell-like diffuse large B-cell lymphoma (non-GCB-
DLBCL) has worse clinical outcome than GCB-DLBCL, and some relapsed/refractory non …

Single-agent lenalidomide has modest activity in diffuse large B-cell lymphoma (DLBCL)
and is thought to be more potent in activated B-cell (ABC) lymphomas, which are more …

Secondary central nervous system (CNS) lymphomas (SCNSL) include the systemic
lymphoproliferative diseases with CNS involvement at presentation or at relapse or at both …

As an immunomodulatory agent with antitumor activity, lenalidomide has been evaluated for
its value in diffuse large B-cell lymphoma (DLBCL). We performed a meta-analysis to gain a …

Diffuse large B-cell lymphomas (DLBCL) s, the most common type of Non-Hodgkin's
Lymphoma, constitute a heterogeneous group of disorders including different disease sites …